Citigroup
TCRT icon

Citigroup’s Alaunos Therapeutics TCRT Stock Holding History

Citigroup’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-393
Closed -$148K – 7330
2020
Q4 		$148K Hold
393
– – ﹤0.01% 5223
2020
Q3 		$148K Hold
393
– – ﹤0.01% 4832
2020
Q2 		$193K Hold
393
– – ﹤0.01% 5038
2020
Q1 		$144K Sell
393
-486
-55% -$251K ﹤0.01% 5020
2019
Q4 		$622K Buy
879
+27
+3% +$18.6K ﹤0.01% 4225
2019
Q3 		$547K Sell
852
-67
-7% -$53.1K ﹤0.01% 4255
2019
Q2 		$804K Buy
919
+332
+57% +$228K ﹤0.01% 3905
2019
Q1 		$339K Sell
587
-18
-3% -$7.53K ﹤0.01% 4581
2018
Q4 		$170K Buy
605
+74
+14% +$29.3K ﹤0.01% 5182
2018
Q3 		$255K Sell
531
-40
-7% -$17.1K ﹤0.01% 4990
2018
Q2 		$259K Buy
571
+204
+56% +$129K ﹤0.01% 4789
2018
Q1 		$216K Buy
367
+48
+15% +$29.9K ﹤0.01% 4889
2017
Q4 		$198K Buy
319
+84
+36% +$60.4K ﹤0.01% 5053
2017
Q3 		$216K Sell
235
-130
-36% -$115K ﹤0.01% 4931
2017
Q2 		$341K Buy
365
+162
+80% +$159K ﹤0.01% 4345
2017
Q1 		$193K Sell
203
-126
-38% -$117K ﹤0.01% 4681
2016
Q4 		$264K Buy
329
+219
+199% +$197K ﹤0.01% 5049
2016
Q3 		$93K Sell
110
-84
-43% -$67.5K ﹤0.01% 5248
2016
Q2 		$160K Sell
194
-78
-29% -$84.9K ﹤0.01% 4701
2016
Q1 		$303K Buy
272
+134
+97% +$137K ﹤0.01% 4681
2015
Q4 		$172K Sell
138
-45
-25% -$74.4K ﹤0.01% 4884
2015
Q3 		$248K Sell
183
-106
-37% -$175K ﹤0.01% 4329
2015
Q2 		$520K Buy
289
+288
+28,800% +$447K ﹤0.01% 3667
2015
Q1 		$1K Buy
+1
New +$1.48K ﹤0.01% 7076

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup's TCRT Position: Q2 2026 in Review

Citigroup sold out of Alaunos Therapeutics (TCRT) in Q2 2026, closing a stake of 1 share — an estimated $3 sold.

Citigroup first reported a position in TCRT in Q2 2013 and held it in 45 quarters. The position peaked at $3.04M in Q1 2021. 29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

  • Citigroup reported no remaining Alaunos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 Alaunos Therapeutics share in Q2 2026, an estimated $3.
  • Citigroup first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 45 quarters.
  • Citigroup's Alaunos Therapeutics position peaked at $3.04M in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.